US 10946009
Combination dosage form of a mu opioid receptor antagonist and an opioid agent
granted A61KA61K31/439A61K31/46
Quick answer
US patent 10946009 (Combination dosage form of a mu opioid receptor antagonist and an opioid agent) held by Theravance Biopharma R&D IP, LLC expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Theravance Biopharma R&D IP, LLC
- Grant date
- Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 14
- CPC classes
- A61K, A61K31/439, A61K31/46, A61K31/485, A61K9/209